MIM
RCUS icon

MetLife Investment Management’s Arcus Biosciences RCUS Stock Holding History

MetLife Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
52,110
+7,301
+16% +$180K 0.01% 1277
2026
Q1 		$968K Buy
44,809
+1,375
+3% +$29.7K ﹤0.01% 1413
2025
Q4 		$1.04M Buy
43,434
+1,972
+5% +$40.2K 0.01% 1410
2025
Q3 		$564K Hold
41,462
– – ﹤0.01% 1750
2025
Q2 		$338K Buy
41,462
+8,451
+26% +$72.2K ﹤0.01% 1883
2025
Q1 		$259K Sell
33,011
-514
-2% -$5.96K ﹤0.01% 2060
2024
Q4 		$499K Buy
33,525
+2,521
+8% +$41.2K ﹤0.01% 1797
2024
Q3 		$474K Hold
31,004
– – ﹤0.01% 1815
2024
Q2 		$472K Buy
31,004
+2,870
+10% +$46.3K ﹤0.01% 1747
2024
Q1 		$531K Hold
28,134
– – ﹤0.01% 1640
2023
Q4 		$537K Hold
28,134
– – ﹤0.01% 1644
2023
Q3 		$505K Hold
28,134
– – ﹤0.01% 1629
2023
Q2 		$571K Buy
28,134
+1,203
+4% +$22.9K ﹤0.01% 1610
2023
Q1 		$491K Hold
26,931
– – ﹤0.01% 1654
2022
Q4 		$557K Buy
26,931
+480
+2% +$13.2K ﹤0.01% 1573
2022
Q3 		$692K Hold
26,451
– – 0.01% 1404
2022
Q2 		$670K Buy
26,451
+1,412
+6% +$34.6K 0.01% 1461
2022
Q1 		$790K Buy
25,039
+9,127
+57% +$306K 0.01% 1475
2021
Q4 		$644K Hold
15,912
– – 0.01% 1367
2021
Q3 		$555K Sell
15,912
-2,486
-14% -$77.4K 0.01% 1463
2021
Q2 		$505K Hold
18,398
– – ﹤0.01% 1561
2021
Q1 		$517K Hold
18,398
– – ﹤0.01% 1504
2020
Q4 		$478K Hold
18,398
– – ﹤0.01% 1512
2020
Q3 		$315K Buy
18,398
+2,753
+18% +$61.5K ﹤0.01% 1603
2020
Q2 		$387K Hold
15,645
– – ﹤0.01% 1521
2020
Q1 		$217K Hold
15,645
– – ﹤0.01% 1654
2019
Q4 		$158K Hold
15,645
– – ﹤0.01% 2109
2019
Q3 		$142K Hold
15,645
– – ﹤0.01% 2136
2019
Q2 		$124K Sell
15,645
-31,290
-67% -$313K ﹤0.01% 2287
2019
Q1 		$586K Buy
46,935
+31,290
+200% +$340K ﹤0.01% 1971
2018
Q4 		$168K Buy
+15,645
New +$183K ﹤0.01% 1997

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

MetLife Investment Management's RCUS Position: Q2 2026 in Review

MetLife Investment Management increased its Arcus Biosciences (RCUS) stake by 16% in Q2 2026, buying an estimated $180K and bringing the position to 52,110 shares worth $1.61M. The position accounts for 0.01% of the portfolio, ranked #1277.

MetLife Investment Management first reported a position in RCUS in Q4 2018 and has held it in 31 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • MetLife Investment Management held 52,110 shares of Arcus Biosciences worth $1.61M as of Q2 2026.
  • MetLife Investment Management bought 7,301 Arcus Biosciences shares in Q2 2026, an estimated $180K.
  • Arcus Biosciences made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1277 holding.
  • MetLife Investment Management first reported a position in Arcus Biosciences in Q4 2018 and has held it in 31 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.